Navigation Links
Sinovac Reports Unaudited First Quarter 2010 Financial Results
Date:5/13/2010

BEIJING, May 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month period ended March 31, 2010.

    First Quarter 2010 Financial Highlights (comparisons to First Quarter 2009)
    -- Sales for the first quarter decreased 32% to $4.4 million
    -- Operating loss for the first quarter was $865,000, compared to
       operating income of $646,000
    -- Net loss attributable to shareholders for the first quarter was
       $307,000, with loss per diluted share of $0.01
    -- Cash and cash equivalents at March 31, 2010 increased to $118.9 million,
       reflecting the closing of the common share public offering in February
       2010


    Business Highlights
    -- In April 2010, Sinovac's joint venture, Sinovac Dalian, submitted an
       application to China's State Food and Drug Administration (SFDA) to
       commence human clinical trials for its mumps vaccine. The proprietary
       mumps vaccine developed by Sinovac Dalian represents not only the first
       live attenuated vaccine for which Sinovac Dalian has filed a clinical
       trial application, but also the first candidate from the joint
       venture's pipeline for which a clinical trial application has been
       submitted to and accepted by the SFDA since the formation of the joint
       venture in January 2010.
    -- In May 2010, Sinovac Biotech, through its wholly owned subsidiary
       Sinovac Biotech (Hong Kong) Ltd, made an initial cash contribution of
       60 million RMB, or approximately $8.8 million, to Sinovac Dalian, the
       Company's 30%-owned joint venture 
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2. Sinovac Announces Upsizing and Pricing of Common Share Offering
3. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
6. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
7. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
9. Sinovac to Present at 2009 UBS Global Life Sciences Conference
10. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
11. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 New interactive learning ... thought leaders of the medical device industry at ... and expo, from June 18-20 in ... http://photos.prnewswire.com/prnh/20130517/613829 ) , These all-new ... professionals practical presentations and implementable solutions on the ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2
... data on lead NNRTI, RDEA806, and next generation compounds to be ... ... Calif., Jan. 29 Ardea Biosciences,Inc. (Nasdaq: RDEA ) today ... family of compounds,including RDEA806, RDEA427 and RDEA640, will be presented during ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... of Neoplastic Cells from Mixed Cellular,Compositions using ... cancer cells ex vivo from blood stem ... modified vaccinia viruses, herpes simplex,viruses, parapoxviruses and ...
... CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, today ... The Instituto de Agrobiotecnologia,Rosario S.A. (INDEAR) based in ... by Bio Sidus AG S.A. and Bioceres S.A. ...
Cached Biology Technology:Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 2Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 3Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent 2SemBioSys signs option agreement for safflower-produced food ingredient 2SemBioSys signs option agreement for safflower-produced food ingredient 3
(Date:5/16/2013)... genome-wide analysis (GWA), where the entirety of an individual,s ... or variants which can cause health problems is a ... can also pose major ethical problems if used incorrectly, ... Genetics (ESHG) published on line today (16 May 2013) ... Many services based on whole genome and on exome* ...
(Date:5/16/2013)... outside of the gym. But doctors use the human pulse ... Bao, a professor of chemical engineering at Stanford, has developed ... wider than a postage stamp. The flexible skin-like monitor, worn ... to help doctors detect stiff arteries and cardiovascular problems. , ... heart health and provide doctors a safer method of measuring ...
(Date:5/15/2013)... touting its benefit in moderating gout risk, new research ... not reduce uric acid (urate) levels to a clinically ... supplementation, alone or in combination with allopurinol, appears to ... in gout patients according to the results published in ... & Rheumatism . , Gout is an inflammatory ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3Vitamin C does not lower uric acid levels in gout patients 2
... the 2007 American Society for Microbiology (ASM) ICAAC Young ... Jason T. Blackard, Ph.D., Research Assistant Professor in the ... Medicine. Dr. Blackard is being honored for his ... Dr. Blackard is a highly qualified researcher, whose current ...
... 2007 American Society for Microbiology (ASM) ICAAC Young Investigator ... Ton-That, Ph.D., Assistant Professor in the Department of Molecular, ... Dr. Ton-That is being honored for his research ... Ton-Thats research is highly regarded, and has been published ...
... September 13, 2007 One of the 2007 American Society ... Merck and Company, Inc., U.S. Human Health, will be ... Professor in Pediatrics, Division of Pulmonary Pediatrics, Childrens Hospital ... is being honored for his research excellence in microbiology ...
Cached Biology News:
...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: